NCT04989829CompletedPhase 1
A Single-centre, One-arm, Open-label, Fixed-sequence Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Male and Female Subjects
Jiangsu HengRui Medicine Co., Ltd.1 site in 1 country20 target enrollmentStarted: December 27, 2021Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- AUC0-t
Study Overview
Brief Summary
This is a one-arm, fixed-sequence study to compare the pharmacokinetic profiles of SHR6390 in absence and presence of prior administration of proton pump inhibitor Omeprazole. The increased gastric pH achieved by the treatment with multiple doses of Omeprazole might affect the absorption process of SHR6390.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Basic Science
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Sign the informed consent before the trial, and fully understand the trial content, process and possible adverse reactions;
- •Ability to complete the study as required by the protocol;
- •Healthy male or female subjects aged 18 to 45 (including 18 and 45) at the date of signing the informed consent;
- •Subjects shall ake effective contraceptive measures voluntarily within 7 months from the date of signing the informed consent form to the date of the last medication. Serum HCG test of fertile women before the study must be negative;
- •Male body weight ≥ 50 kg, female body weight ≥ 45 kg, and body mass index (BMI) within the range of 19 ~ 26 kg /m2 (including 19 and 26);
- •Healthy subjects identified by a detailed medical history;
- •Full physical examinations, including blood pressure and pulse rate measurement, 12-lead ECG or clinical laboratory test, are normal or abnormal but have no clinical significance.
Exclusion Criteria
- •Blood donation or loss≥400 mL within 3 months prior to screening, or blood donation or loss≥200 mL, or blood transfusion within 1 months before screening;
- •Participating in any clinical trial or taking drugs that might damage organs within 3 months before screening;
- •Surgeries in the previous 6 months before screening;
- •Use of vaccines or biologicals within 2 weeks prior to screening;
- •Allergic constitution;
- •History of drug abuse or alcoholism, or positive for nicotine, alcohol and drug tests;
- •History of myocarditis, coronary heart disease, arrhythmia, stroke and so on, or 12 lead ECG demonstrating a corrected QT by Fridericia (QTcF) interval ≥450 msec;
- •With dysphagia or history of gut disease or surgery (gastrectomy, enterectomy, sleeve gastrectomy, etc) possibly affecting drug absorption;
- •Uncontrolled gut disease, such as peptic ulcer, colitis, pancreatitis, etc;
- •History of chronic kidney disease, renal insufficiency, anemia of renal failure, or creatinine clearance rate (CLCr) < 80 mL/min, or serum creatinine ≥ ULN.
Arms & Interventions
Treatment group
Experimental
Intervention: SHR6390、Omeprazole (Drug)
Outcomes
Primary Outcomes
AUC0-t
Time Frame: from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose
Area under the plasma concentration versus time curve (AUC0-t) for SHR6390 after Single dose
Cmax
Time Frame: from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose
Maximum observed serum concentration (Cmax) for SHR6390 after Single dose.
AUC0-∞
Time Frame: from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose
Area under the plasma concentration versus time curve (AUC0-∞) for SHR6390 after Single dose
Secondary Outcomes
- Tmax(from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose)
- CL/F(from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose)
- Vz/F(from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose)
- T1/2(from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose)
- Number of subjects with adverse events and severity of adverse events(from Day1 to Day30 after the first dose)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Phase I Clinical Study on SHR6390 in Healthy Chinese VolunteersHealthy VolunteersNCT05354336The Affiliated Hospital of Qingdao University36
Completed
Phase 1
Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic ImpairmentComplement Mediated Primary or Secondary Glomerular DiseasesNCT06674915Chengdu Suncadia Medicine Co., Ltd.24
Unknown
Phase 1
An Investigational Study of SHR6390 in Participants With Mild to Moderate Liver Impairment and Healthy ParticipantsHepatic ImpairmentHealthy ParticipantsNCT04631575Jiangsu HengRui Medicine Co., Ltd.24
Completed
Phase 1
Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast CancerAdvanced Breast CancerNCT06710990Jiangsu HengRui Medicine Co., Ltd.17
Completed
Phase 1
Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy SubjectsType 2 DiabetesNCT06654960Fujian Shengdi Pharmaceutical Co., Ltd.20